RTNS 2012
Recent articles
Better tools needed to assess clinical trials
The past few years have seen an unprecedented number of clinical trials for experimental drugs to treat autism-related disorders, most notably for fragile X syndrome. But as the trials progress, scientists are calling for better methods to measure the drugs’ effectiveness.
Better tools needed to assess clinical trials
The past few years have seen an unprecedented number of clinical trials for experimental drugs to treat autism-related disorders, most notably for fragile X syndrome. But as the trials progress, scientists are calling for better methods to measure the drugs’ effectiveness.
Trials and tribulations
Clinical trials for fragile X drugs should include a behavioral therapy component, says a parent of a child with the disorder.
Trials and tribulations
Clinical trials for fragile X drugs should include a behavioral therapy component, says a parent of a child with the disorder.
Compensatory mechanisms
Identifying genetic and other factors that protect children at risk of autism from developing the disorder could provide new avenues for treatment.
Compensatory mechanisms
Identifying genetic and other factors that protect children at risk of autism from developing the disorder could provide new avenues for treatment.
Debate over quality of adult-derived stem cells rages on
As the use of induced pluripotent stem cells grows, researchers are searching for ways to make them behave more predictably.
Debate over quality of adult-derived stem cells rages on
As the use of induced pluripotent stem cells grows, researchers are searching for ways to make them behave more predictably.
Complex case
Multiple levels of complexity make it challenging to develop drugs to treat autism.
Complex case
Multiple levels of complexity make it challenging to develop drugs to treat autism.
Fast-forward
In the last three years, autism researchers have gone from sequencing single genes to whole exomes, as highlighted at the Translational Neuroscience Symposium in Switzerland last week.
Fast-forward
In the last three years, autism researchers have gone from sequencing single genes to whole exomes, as highlighted at the Translational Neuroscience Symposium in Switzerland last week.
Explore more from The Transmitter
Remembering GABA pioneer Edward Kravitz
The biochemist, who died last month at age 92, was part of the first neurobiology department in the world and showed that gamma-aminobutyric acid is inhibitory.
Remembering GABA pioneer Edward Kravitz
The biochemist, who died last month at age 92, was part of the first neurobiology department in the world and showed that gamma-aminobutyric acid is inhibitory.
Protein tug-of-war controls pace of synaptic development, sets human brains apart
Human-specific duplicates of SRGAP2 prolong cortical development by manipulating SYNGAP, an autism-linked protein that slows synaptic growth.
Protein tug-of-war controls pace of synaptic development, sets human brains apart
Human-specific duplicates of SRGAP2 prolong cortical development by manipulating SYNGAP, an autism-linked protein that slows synaptic growth.
Neurons tune electron transport chain to survive onslaught of noxious stimuli
Nociceptors tamp down the production of reactive oxygen species in response to heat, chemical irritants or toxins.
Neurons tune electron transport chain to survive onslaught of noxious stimuli
Nociceptors tamp down the production of reactive oxygen species in response to heat, chemical irritants or toxins.